Compare VTR & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTR | IQV |
|---|---|---|
| Founded | 1983 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Real Estate Investment Trusts | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.1B | 41.3B |
| IPO Year | 2005 | 2013 |
| Metric | VTR | IQV |
|---|---|---|
| Price | $86.35 | $171.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | $83.31 | ★ $233.33 |
| AVG Volume (30 Days) | 2.8M | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ 184.21 | 4.67 |
| EPS | 0.54 | ★ 7.84 |
| Revenue | $5,833,980,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $11.61 | $6.77 |
| Revenue Next Year | $8.24 | $5.91 |
| P/E Ratio | $160.93 | ★ $22.29 |
| Revenue Growth | 18.47 | ★ 41.60 |
| 52 Week Low | $60.15 | $134.65 |
| 52 Week High | $87.87 | $247.05 |
| Indicator | VTR | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 71.26 | 38.38 |
| Support Level | $66.18 | $156.43 |
| Resistance Level | $87.24 | $193.26 |
| Average True Range (ATR) | 1.45 | 7.54 |
| MACD | -0.06 | 2.08 |
| Stochastic Oscillator | 63.22 | 54.05 |
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.